MX364061B - Composición farmacéutica para la preparación de disoluciones para infusión de preparaciones antimicrobianas y su procedimiento de producción (variaciones). - Google Patents

Composición farmacéutica para la preparación de disoluciones para infusión de preparaciones antimicrobianas y su procedimiento de producción (variaciones).

Info

Publication number
MX364061B
MX364061B MX2015005804A MX2015005804A MX364061B MX 364061 B MX364061 B MX 364061B MX 2015005804 A MX2015005804 A MX 2015005804A MX 2015005804 A MX2015005804 A MX 2015005804A MX 364061 B MX364061 B MX 364061B
Authority
MX
Mexico
Prior art keywords
preparation
solutions
colloidal silica
pharmaceutical compositions
preparations
Prior art date
Application number
MX2015005804A
Other languages
English (en)
Inventor
Lvovich Limonov Viktor
Valentinovich Gaidul Konstantin
Valerevich Dushkin Aleksandr
Original Assignee
Lvovich Limonov Viktor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lvovich Limonov Viktor filed Critical Lvovich Limonov Viktor
Publication of MX364061B publication Critical patent/MX364061B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a farmacología, medicina, veterinaria e industria farmacéutica, concretamente a composiciones farmacéuticas para la preparación de disoluciones para infusión de preparaciones antimicrobianas que potencian la eficacia terapéutica de productos farmacéuticos antimicrobianos, durante el procedimiento de preparación de sus disoluciones inmediatamente antes de preparar infusiones intravenosas y los procedimientos de producción de principios farmacéuticos compuestos originales. Las composiciones farmacéuticas ofrecidas para la preparación de disoluciones para inyección de todas las preparaciones antimicrobianas sometidas a prueba que contienen el polvo finamente disperso de sílice coloidal nanoestructurada, aumentan de manera fiable su eficacia terapéutica cuando se trata septicemia fulminante de animales de prueba, provocada por Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa y Candida albicans. Las composiciones farmacéuticas ofrecidas para la preparación de disoluciones de preparaciones antibacterianas y antifúngicas para infusiones intravenosas (NaC1:sílice coloidal y dextrosa: sílice coloidal) tienen una acción potenciadora significativa clínicamente importante sobre su potencial terapéutico cuando se tratan enfermedades inflamatorias e infecciosas malignas, en comparación con disolventes tradicionales (prototipos de la invención).
MX2015005804A 2011-11-22 2012-10-26 Composición farmacéutica para la preparación de disoluciones para infusión de preparaciones antimicrobianas y su procedimiento de producción (variaciones). MX364061B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011147170/15A RU2476206C1 (ru) 2011-11-22 2011-11-22 Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)

Publications (1)

Publication Number Publication Date
MX364061B true MX364061B (es) 2019-04-11

Family

ID=46940397

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012012486A MX338043B (es) 2011-11-22 2012-10-26 Composicion farmaceutica para la preparacion de disoluciones para infusion de preparaciones antimicrobianas y su procedimiento de produccion (variaciones).
MX2015005804A MX364061B (es) 2011-11-22 2012-10-26 Composición farmacéutica para la preparación de disoluciones para infusión de preparaciones antimicrobianas y su procedimiento de producción (variaciones).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012012486A MX338043B (es) 2011-11-22 2012-10-26 Composicion farmaceutica para la preparacion de disoluciones para infusion de preparaciones antimicrobianas y su procedimiento de produccion (variaciones).

Country Status (21)

Country Link
US (2) US9889158B2 (es)
EP (1) EP2596783B1 (es)
JP (1) JP5568114B2 (es)
CN (2) CN107913250B (es)
AU (1) AU2012211402B2 (es)
BR (1) BR102012020929B1 (es)
CA (1) CA2792574C (es)
CY (1) CY1120810T1 (es)
DK (1) DK2596783T3 (es)
ES (1) ES2685222T3 (es)
HR (1) HRP20181274T1 (es)
HU (1) HUE039112T2 (es)
LT (1) LT2596783T (es)
MX (2) MX338043B (es)
PL (1) PL2596783T3 (es)
PT (1) PT2596783T (es)
RS (1) RS57578B1 (es)
RU (1) RU2476206C1 (es)
SI (1) SI2596783T1 (es)
TR (1) TR201810244T4 (es)
UA (1) UA105260C2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2476206C1 (ru) 2011-11-22 2013-02-27 Виктор Львович Лимонов Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)
GR1008554B (el) 2014-06-12 2015-09-03 ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
CA3129395A1 (en) * 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) * 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
JPS60169431A (ja) * 1984-02-14 1985-09-02 Nippon Zenyaku Kogyo Kk β−ラクタム環を有する化合物を含有する安定な抗菌剤及びその製造法
IT1243180B (it) 1990-07-31 1994-05-24 Nunzio Rapisarda Uso della fosfomicina e dei suoi sali come agente cicatrizzante topico
CN1071076A (zh) * 1991-09-26 1993-04-21 丛繁滋 双黄连气雾剂的制备方法
FR2687071B1 (fr) 1992-02-10 1995-06-23 Exsymol Sa Vecteur pour principe(s) actif(s) therapeutique(s) ou cosmetique(s) a usage externe et composition therapeutique ou cosmetique comprenant un tel vecteur.
JP3435664B2 (ja) * 1999-12-08 2003-08-11 ヤンセンファーマ株式会社 口腔内速崩壊型錠剤及びその製造方法
KR20010097244A (ko) * 2000-04-21 2001-11-08 유충식 위산도 비의존성 고용해도를 갖는 이트라코나졸 함유약학적 조성물 및 그 제조방법
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
WO2003063877A1 (en) * 2002-02-01 2003-08-07 Akzo Nobel N.V. Cefquinome composition for intra-mammary administration in cattle
US20050238724A1 (en) * 2002-04-23 2005-10-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
UA81258C2 (en) 2002-08-09 2007-12-25 Akzo Nobel Coatings Int Bv Quaternized polymer with acidic blocking groups, method for obtaining and use thereof, and composition, containing this polymer
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
EA013864B1 (ru) * 2008-08-29 2010-08-30 Лимонова, Анастасия Викторовна Способ повышения антимикробной активности цефалоспориновых антибиотиков
EA021875B1 (ru) 2010-09-20 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антимикробного и ранозаживляющего действия для наружного применения, способ ее получения
EA021876B1 (ru) * 2010-09-20 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антимикробного и противовоспалительного действия для парентерального введения, способ ее получения
RU2476206C1 (ru) 2011-11-22 2013-02-27 Виктор Львович Лимонов Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)

Also Published As

Publication number Publication date
NZ601748A (en) 2012-12-21
HRP20181274T1 (hr) 2018-11-02
CN103126995A (zh) 2013-06-05
BR102012020929B1 (pt) 2019-08-06
PL2596783T3 (pl) 2018-11-30
CN107913250B (zh) 2021-01-22
CA2792574A1 (en) 2013-05-22
CN103126995B (zh) 2018-01-12
EP2596783B1 (en) 2018-06-06
CN107913250A (zh) 2018-04-17
US20150283172A1 (en) 2015-10-08
RS57578B1 (sr) 2018-11-30
CA2792574C (en) 2017-01-17
RU2476206C1 (ru) 2013-02-27
CN103126995B8 (zh) 2018-04-06
US9844566B2 (en) 2017-12-19
AU2012211402A1 (en) 2013-06-06
CY1120810T1 (el) 2019-12-11
JP2013107870A (ja) 2013-06-06
LT2596783T (lt) 2018-09-25
MX2012012486A (es) 2013-05-21
SI2596783T1 (sl) 2018-10-30
PT2596783T (pt) 2018-10-09
ES2685222T3 (es) 2018-10-05
HUE039112T2 (hu) 2018-12-28
US20140105936A1 (en) 2014-04-17
DK2596783T3 (en) 2018-08-27
BR102012020929A2 (pt) 2013-10-29
TR201810244T4 (tr) 2018-08-27
EP2596783A1 (en) 2013-05-29
AU2012211402B2 (en) 2013-12-05
UA105260C2 (ru) 2014-04-25
JP5568114B2 (ja) 2014-08-06
US9889158B2 (en) 2018-02-13
MX338043B (es) 2016-03-30

Similar Documents

Publication Publication Date Title
Sevgi et al. Topical antimicrobials for burn infections–an update
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
JP2010222367A5 (es)
JP2014505733A5 (es)
EA201991299A1 (ru) Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов
MX340985B (es) Compuestos de n-heteroarilo.
MX364061B (es) Composición farmacéutica para la preparación de disoluciones para infusión de preparaciones antimicrobianas y su procedimiento de producción (variaciones).
BRPI1010948A2 (pt) Composição compreendendo pelo menos trans- cinamaldeído e a respectiva utilização no tratamento das infecções bacterianas, mais particularmente no tratamento das doenças nosocomiais.
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
WO2016060517A3 (ko) 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
MX2016005764A (es) Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.
BR112016000092A2 (pt) nanopartículas lipídicas para a cicatrização de feridas
JP2015526463A5 (es)
이영수 et al. Synergistic antibacterial activity of fig (Ficus carica) leaves extract against clinical isolates of methicillin-resistant Staphylococcus aureus
MY184630A (en) Tylosin derivatives and method for preparation thereof
EA201100735A1 (ru) Фармацевтическая композиция антибактериального действия для парентерального применения, способ ее получения
MX2012010707A (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.
JP2017517574A5 (es)
EA201001507A1 (ru) Фармацевтическая композиция антимикробного и противовоспалительного действия для парентерального введения, способ ее получения
EA201100733A1 (ru) Фармацевтическая композиция для лечения туберкулеза и других инфекций, способ ее получения
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
WO2015004634A3 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
EA201100736A1 (ru) Фармацевтическая композиция антимикробного действия для парентерального применения, способ ее получения
RU2011148433A (ru) Способ лечения субклинического мастита у коров